Company news
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Announcement on Acceptance of Drug Registration Application of Holding Subsidiary
May 13, 2026
Notice on Convening the 2025 Annual General Meeting, the 2nd A-Share Shareholders' Meeting in 2026, and the 2nd H-Share Shareholders' Meeting in 2026
May 11, 2026
Announcement on Holding Subsidiary’s Drug Obtaining Approval for Clinical Trial from FDA
May 10, 2026
Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution
April 28, 2026
Arcera Life Sciences and Fosun Pharma launch long-term collaboration framework
April 28, 2026
Announcement on Progress in Participation in Establishing a Private Equity Investment Fund and Proposed Disposal of Assets
April 23, 2026
Fosun Health เสริมความแกร่งระดับภูมิภาคที่ GlobalHealth Asia-Pacific Forum 2026 อวด "China Solution" พร้อมกวาดสามรางวัลใหญ่
April 23, 2026
Announcement on the Pledge of Partial Shares Held by Shareholders
April 15, 2026
Announcement on Approval of Supplementary Drug Application by Holding Subsidiary
April 9, 2026
Announcement on Change of Chief Financial Officer
April 2, 2026
Announcement on Participating in Setting up Private Equity Investment Fund
March 31, 2026
Announcement on Proposed Expansion of Financial Leasing Business by a Holding Subsidiary
March 24, 2026
Announcement on Resolutions of the Convening of the 2026 1st Extraordinary General Meeting, the 2026 1st A-share General Meeting and the 2026 1st H-share General Meeting
February 27, 2026
Self-Inspection Report on Trading of the Company's Shares by Insiders Related to the Spin-off and Listing of a Subsidiary on the Main Board of the Stock Exchange of Hong Kong Limited
February 26, 2026
Indicative Announcement on Convening of the 2026 1st Extraordinary General Meeting, the 2026 1st A-share General Meeting and the 2026 1st H-share General Meeting
February 25, 2026
Announcement on Progress in Signing the Licensing Agreement of Wholly-owned Subsidiary
February 24, 2026
Announcement on Signing License Agreement by Holding Subsidiary
February 5, 2026
Notice of the Convening of the 2026 1st Extraordinary General Meeting, the 2026 1st A-share General Meeting and the 2026 1st H-share General Meeting
February 4, 2026
Announcement on Completion of Issuance of the 2026 Phase I Science and Technology Innovation Bonds
February 3, 2026
Announcement on Resolutions of the 23rd (Extraordinary) Meeting of the 10th Board of Directors
January 27, 2026
Announcement on Pledge and Release of Pledge of Partial Shares of Shareholder
January 23, 2026
Announcement on Resolutions of the 22nd (Extraordinary) Meeting of the 10th Board of Directors
January 22, 2026
Announcement on Completion of Filing with China Securities Regulatory Commission for Application for Full Circulation of Domestic Unlisted Shares of Holding Subsidiary
January 16, 2026
Announcement on Progress in Implementation of the Incentive Plan by a Holding Subsidiary
January 14, 2026
Announcement on Completing Private Investment Fund Filing for Subscribed Equity Investment Fund
January 5, 2026
Announcement on Progress in Participating in the Establishment of Private Equity Investment Fund
December 31, 2025
Announcement on Holding Subsidiary's Progress in Drug Clinical Trials
December 30, 2025
Announcement on Completion of 2022 Non-public Offering Funded Projects and Closure of Special Accounts
December 24, 2025
Announcement on Reply to Shanghai Stock Exchange's "Letter of Regulation in Outward Investment"
December 22, 2025
Announcement on Signing Cooperation and Option Agreement by Holding Subsidiary
December 18, 2025
Announcement on Outward Investment
December 15, 2025
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement
December 9, 2025
Fosun Pharma Announces 2025Q3 Financial Results
October 28, 2025
Fosun Pharma Announces 2025 Interim Results
August 26, 2025
Fosun Pharma's Self-Developed Innovative Drug Luvometinib Tablets Gains Breakthrough Therapy Designation in Saudi Arabia
August 19, 2025
Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million
August 11, 2025
Fosun Pharma’s Self-Developed New Drug XH-S004 for the Treatment of Chronic Obstructive Pulmonary Disease Enters Phase 1b Clinical Trial
July 17, 2025
Fosun Pharma's Self-developed Innovative Drug Luvometinib Tablets for the Treatment of Pediatric Low-grade Glioma Indication Enters Phase 3 Clinical Trial in China
July 9, 2025
Shanghai Fosun Pharmaceutical (Group): Fosun Pharma Completes Board Election, Accelerating Innovation Transformation and Global Development
June 24, 2025
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
June 16, 2025
Fosun Pharma Announces 2024 Annual Results
March 24, 2025
Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)
February 26, 2025
Fosun Pharmaceutical Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation
February 17, 2025
Fosun Pharma’s Self developed anti PD 1 mAb Serplulimab Approved in the EU for First Line Treatment of Extensive Stage Small Cell Lung Cancer (ES SCLC)
February 6, 2025
Fosun Pharma and Insightec Establish Joint Venture to Expand Global Access to Focused Ultrasound Treatment for Neurological Diseases
December 11, 2023
Shanghai Fosun Pharmaceutical (Group): COMIRNATY® Bivalent COVID-19 Vaccine is Officially Approved as Regular Imported Vaccine by the Pharmaceutical Administration Bureau of Macao SAR
January 20, 2023
Self-Paid Vaccination Service for Bivalent COVID-19 Vaccine COMIRNATY® is Officially Provided in Hong Kong, Offering More Vaccine Options for People in Need
January 5, 2023
Shanghai Fosun Pharmaceutical (Group): Fosun Pharma Announces Results for the First Three Quarters of 2022
October 29, 2022
Voluntary announcement - entering into sale and purchase agreements (h shares)
June 6, 2022
Monthly return of equity issuer on movements in securities for the month ended 31 May 2022(h shares)
June 1, 2022
Decks
- H1 2026 Earnings Presentation
Earnings · 45 slides · Oct 12, 2026
- Q1 2026 Earnings Presentation
Earnings · 45 slides · 2026
- Q1 2025 Earnings Presentation
Earnings · 44 slides · 2025
- Q3 2025 Earnings Presentation
Earnings · 45 slides · 2025